Repligen (RGEN) Q3 2026 Earnings Call: Record Revenue and Raised Guidance
Source Tradingkey
Key Takeaways
- Repligen reported record Q3 2026 revenue of $209 million, up 11% year over year on a reported basis and 12.5% organically.
- Adjusted operating income increased 24% to $33 million, while adjusted operating margin expanded 170 basis points to 15.9%.
- Consumables revenue grew 20%, and services grew more than 20%. Capital equipment orders increased in the mid-teens and reached their highest quarterly level in five years, although equipment revenue declined as deliveries shifted into 2027.
- Chromatography revenue grew more than 50%, proteins exceeded 40% growth, and analytics rose 20%. Filtration declined 11%, reflecting ATF-related headwinds, the Polymem divestiture, foreign exchange and equipment timing.
- Repligen raised its 2026 revenue guidance to $844 million-$852 million, including approximately $24 million from BioLife following the October 6 acquisition close.
- Management said Repligen is positioned to grow reported revenue by at least 25% in 2027 and exceed $1 billion, assuming high-single-digit market growth and no material foreign-exchange change. This is a planning framework, not formal 2027 guidance.
Core Financial Results
| Metric | Q3 2026 | Change / context |
|---|---|---|
| Revenue | $209 million | Record quarter; up 11% reported and 12.5% organically |
| Adjusted gross profit | $111 million | — |
| Adjusted gross margin | 53.0% | Down 30 basis points year over year |
| Adjusted operating income | $33 million | Up 24% year over year |
| Adjusted operating margin | 15.9% | Up 170 basis points |
| Adjusted EBITDA | $44 million | 20.9% margin |
| Adjusted net income | $30 million | Up 16% year over year |
| Adjusted diluted EPS | $0.53 | Up 15% from $0.46 |
| Cash, cash equivalents and marketable securities | $863 million | Up $53 million sequentially |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Nasdaq rises 0.82% as Anthropic files for IPO, gold reclaims $4,000 and oil falls. Explore Australia's market outlook ahead of the Fed decision.
CNBC host Jim Cramer says he would buy Goldman Sachs shares after Anthropic filed its initial public offering (IPO) prospectus on Monday, a deal that earns the bank fees as a lead underwriter.Goldman’
Bitcoin is fighting to hold $80,000 after three consecutive weeks of losses. The broader crypto market remains under pressure as weak investor confidence and volatility in global stocks weigh on price
Gold has lost nearly a quarter of its value since the US-Iran war began. On Friday, it briefly fell to $3,975 an ounce before recovering to around $4,020 on Monday.Yet investors have been pouring bill
South Korea’s KOSPI rose 4.53% from Monday’s close to 5,717.30 on Tuesday morning. The jump made the Korea Exchange pause program buying for five minutes, its second brake in six days.The first brake,
